Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Reg FD DisclosureItem 7.01 · 8-KLOW RiskPositive

Entrada Therapeutics, Inc.

Filed: May 18, 2026CIK: 0001689375
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Entrada Therapeutics updated its corporate presentation for investor and analyst meetings on May 18, 2026, signaling a proactive approach to stakeholder communication about strategic direction and current initiatives.

Key Takeaways

Company provided an updated corporate presentation for use in upcoming investor and analyst meetings

The presentation is furnished but not filed under the Exchange Act, limiting legal liability implications

2 more takeaways

Filing Overview

Form Type8-K
Filing DateMay 18, 2026
Item7.01
CategoryReg FD Disclosure
CIK0001689375
Accession #001-40969
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
expansion

What This Means

The company is making a public disclosure under Regulation FD, often sharing material information to ensure equal access.
View Full Filing on SEC.govBrowse More Filings